Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)
14 November 2022 - 11:44PM
Edgar (US Regulatory)
Viveve Medical, Inc.
345 Inverness Drive South
Building B, Suite 250
Englewood, Colorado 80112
November 14, 2022
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Registration Statement on Form S-1 (File No. 333-268311)
|
Ladies and Gentlemen:
Reference is made to the registration statement on Form S-1 (File No. 333-268311) filed with the Securities and Exchange Commission by Viveve Medical, Inc. (the “Company”) on November 10, 2022 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933, as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated onto the cover page of the Registration Statement:
“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said section 8(a), may determine.”
If you have any questions regarding this request, please contact Shoaib Ghias of Goodwin Procter LLP at (415) 733‑6150.
|
Sincerely,
|
|
Viveve Medical, Inc.
|
|
|
|
/s/ Scott Durbin
|
|
Scott Durbin
|
|
Chief Executive Officer
|
|
cc:
|
Jim Robbins, Viveve Medical, Inc.
|
|
|
Mitchell Bloom, Goodwin Procter LLP
|
|
|
Shoaib Ghias, Goodwin Procter LLP
|
Viveve Medical (NASDAQ:VIVE)
Historical Stock Chart
Von Feb 2025 bis Mär 2025
Viveve Medical (NASDAQ:VIVE)
Historical Stock Chart
Von Mär 2024 bis Mär 2025
Echtzeit-Nachrichten über Viveve Medical Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Viveve Medical, Inc. News-Artikel